Gyre Therapeutics Collaborates with Harbour BioMed to Advance Antibody Therapeutics Development
- Harbour BioMed acquires 3.8% of Spruce Biosciences, transitioning to a collaborative partnership for antibody development.
- The collaboration focuses on developing SPR202, targeting corticotropin-releasing hormone for congenital adrenal hyperplasia treatment.
- Harbour BioMed aims to enhance its immunology and oncology offerings through innovative collaborations and advanced technologies.
Strengthening Collaborations in Antibody Therapeutics: Harbour BioMed and Spruce Biosciences Form Strategic Partnership
Harbour BioMed, a global biopharmaceutical leader specializing in novel antibody therapeutics, recently announces a significant collaboration with Spruce Biosciences, Inc. This strategic partnership arises from Harbour BioMed’s exercise of a warrant to acquire common stock in Spruce, resulting in ownership of approximately 3.8% of Spruce’s total outstanding shares. This acquisition is not merely a financial investment; it signals a transformative shift in the relationship between the two companies. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, highlights that this move transitions their connection from a standard licensor-licensee relationship to a more integrated and collaborative partnership.
The collaboration is focused on the development of SPR202, a monoclonal antibody specifically designed to target corticotropin-releasing hormone. This innovative therapy aims to address conditions such as congenital adrenal hyperplasia, which can significantly impact patients' quality of life. By pooling resources and expertise, Harbour BioMed and Spruce Biosciences aim to expedite the advancement of SPR202 through the late-stage development process. The partnership leverages Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, renowned for generating fully human monoclonal antibodies, alongside Spruce's research capabilities, to create a robust pipeline of transformative therapies.
Harbour BioMed's strategic intent is clear: to enhance its therapeutic offerings in immunology and oncology through innovative collaborations. The company is well-known for its advanced technologies, including HCAb-based immune cell engagers (HBICE®) and immune cell antagonists (HBICATM). These platforms are designed to develop more effective treatments for immunological and inflammatory diseases than traditional therapies. By establishing this partnership with Spruce, Harbour BioMed not only strengthens its position in the biopharmaceutical landscape but also reinforces its commitment to improving patient outcomes worldwide through cutting-edge research and development.
In addition to the collaboration with Spruce, Harbour BioMed continues to expand its global presence and R&D initiatives. The company is actively seeking additional partnerships that align with its mission to innovate in the field of antibody therapeutics. As the biopharmaceutical industry rapidly evolves, Harbour BioMed remains focused on building a diverse pipeline that addresses unmet medical needs.
The announcement underscores the growing trend of strategic partnerships in the biopharmaceutical sector, as companies recognize the value of collaboration to drive innovation and expedite the development of new therapies. With its strategic investments and focus on advancing antibody therapeutics, Harbour BioMed is poised to play a pivotal role in the future of immunotherapy and patient care.